Generated by AI
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. The company centers its work on immune-based approaches, including antibody therapeutics and T cell-engaging technologies, to address conditions with significant unmet medical need. Its current portfolio includes programs for chronic hepatitis delta and chronic hepatitis B, alongside multiple solid-tumor candidates built on its PRO-XTEN masking platform. Vir Biotechnology also maintains preclinical research across infectious diseases and oncology, reflecting a pipeline that spans both treatment and prevention. Headquartered in San Francisco, California, Vir Biotechnology plays a role in the broader biotechnology market as a research-driven developer of advanced therapeutic candidates.
Website1800 Owens Street
San Francisco, CA, 94158
United States
The latest articles about VIR.
Summary of Nov 13's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Summary of Aug 27's posts. Generated by AI.
Summary of Nov 13's posts. Generated by AI.
Investors talking about VIR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.